An Act amending the act of October 24, 2018 (P.L.719, No.112), known as the Patient Test Result Information Act, further providing for definitions; providing for prostate-specific antigen test results; and further providing for duties of Department of Health.

PRINTER'S NO. 3501
THE GENERAL ASSEMBLY OF PENNSYLVANIA
HOUSE BILL
No. 2592
Session of
2026
INTRODUCED BY K. HARRIS, DIAMOND, KHAN, SANCHEZ, COOK, HILL-
EVANS, HANBIDGE, GUENST, WAXMAN, DOUGHERTY, FREEMAN, BRENNAN,
BURGOS, CEPEDA-FREYTIZ, RIVERA, CIRESI, HOHENSTEIN, COOPER,
NEILSON, MALAGARI, MAYES, GILLEN, PARKER AND STEELE,
JUNE 2, 2026
REFERRED TO COMMITTEE ON HEALTH, JUNE 2, 2026
AN ACT
Amending the act of October 24, 2018 (P.L.719, No.112), entitled
"An act providing for notification of patient test results to
be sent directly to a patient or the patient's designee; and
providing for duties of the Department of Health," further
providing for definitions; providing for prostate-specific
antigen test results; and further providing for duties of
Department of Health.
The General Assembly of the Commonwealth of Pennsylvania
hereby enacts as follows:
Section 1. Section 2 of the act of October 24, 2018
(P.L.719, No.112), known as the Patient Test Result Information
Act, is amended by adding definitions to read:
Section 2. Definitions.
The following words and phrases when used in this act shall
have the meanings given to them in this section unless the
context clearly indicates otherwise:
"Department." The Department of Health of the Commonwealth.
* * *
"Prostate-specific antigen test." A blood test that measures
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
the amount of prostate-specific antigen in an individual's
blood, which may indicate that an individual is at an increased
risk of prostate cancer.
* * *
Section 2. The act is amended by adding a section to read:
Section 3.1. Prostate-specific antigen test results.
(a) Notice.--When, in the judgment of the entity performing
a prostate-specific antigen test, an abnormal level of prostate-
specific antigen may exist, the entity performing the prostate-
specific antigen test shall directly notify the patient or the
patient's designee by providing notice that the entity has
completed a review of the test performed on the patient and has
sent results to the health care practitioner who ordered the
prostate-specific antigen test. The notice shall include all of
the following:
(1) The name of the ordering health care practitioner.
(2) The date the test was performed.
(3) The date the results were sent to the ordering
health care practitioner.
(4) A summary of the results of the prostate-specific
antigen test in lay language.
(5) The following statements:
You are receiving this notice as a result of a
determination by your prostate-specific antigen test
that further discussions of your test results are
warranted and would be beneficial to you.
The complete results of your test or tests have been
or will be sent to the health care practitioner that
ordered the test or tests. It is recommended that you
contact your health care practitioner to discuss your
20260HB2592PN3501 - 2 -
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
results as soon as possible.
(6) The contact information necessary for the patient to
obtain a full report.
(b) Time.--No later than five days after the date the
results are sent to the ordering health care practitioner under
subsection (a)(3), the entity performing the prostate-specific
antigen test shall provide the patient or patient's designee
with the notice under subsection (a).
(c) Method of transmittal.--
(1) The notice under subsection (a) shall be provided in
a manner deemed acceptable by the patient or the patient's
designee.
(2) The notice provided under subsection (a) shall be
presumed to comply with this act if:
(i) mailed in a properly addressed and stamped
letter through the United States Postal Service;
(ii) sent electronically by email;
(iii) sent by automatic alert from an electronic
medical record system that the notice under subsection
(a) has been posted to the patient's electronic medical
record that is presently viewable; or
(iv) sent by facsimile.
(d) Construction.--Nothing in this section shall be
construed to:
(1) Require an entity to provide a patient or patient's
designee the notice under subsection (a) if the results are
provided to the patient or patient's designee by the health
care practitioner or the entity at the time of the test.
(2) Prohibit an entity from providing a patient with:
(i) The summary of a prostate-specific antigen test.
20260HB2592PN3501 - 3 -
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
(ii) The complete results of the prostate-specific
antigen test provided to the ordering health care
practitioner.
Section 3. Section 4 of the act is amended to read:
Section 4. Duties of [Department of Health] department.
(a) Compliance.--The [Department of Health] department
shall:
(1) in accordance with law, conduct compliance reviews
as part of the inspection performed by the department or an
accrediting organization and investigate complaints filed
relating to the requirements of section 3; and
(2) establish a complaint procedure, which shall be made
available on the department's publicly accessible Internet
website.
(b) List.--The department shall:
(1) establish and maintain a list of age ranges with
corresponding appropriate and abnormal prostate-specific
antigen levels based on available scientific data for use by
an entity performing prostate-specific antigen testing;
(2) update the list as needed; and
(3) publish the list on the department's publicly
accessible Internet website.
Section 4. This act shall take effect in 60 days.
20260HB2592PN3501 - 4 -
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23